No data to show
XLON
4BB
Market cap232mUSD
Jun 03, Last price
1,110.00GBP
1D
0.00%
1Q
-0.45%
IPO
186.45%
Name
4Basebio PLC
Chart & Performance
P/E
—
P/S
33,940.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
506k
+88.81%
Net income
-8m
L+48.83%
CFO
-6m
L+31.34%
Profile
4basebio PLC engages in the design, development, manufacturing, and supply of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company provides research kits, bulk enzymes, and other products, as well as licensing services; and AVV manufacturing services. It serves biotech, pharma, and contract development and manufacturing organization customers. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was incorporated in 2020 and is based in Cambridge, United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 506 88.81% | 268 -20.71% | |||
Cost of revenue | 5,268 | 5,066 | |||
Unusual Expense (Income) | |||||
NOPBT | (4,762) | (4,798) | |||
NOPBT Margin | |||||
Operating Taxes | (689) | (779) | |||
Tax Rate | |||||
NOPAT | (4,073) | (4,019) | |||
Net income | (7,665) 48.83% | (5,150) 59.20% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 2 | ||||
BB yield | 0.00% | ||||
| Debt | |||||
Debt current | 392 | 415 | |||
Long-term debt | 10,955 | 3,550 | |||
Deferred revenue | 116 | ||||
Other long-term liabilities | 72 | 116 | |||
Net debt | 8,278 | (386) | |||
| Cash flow | |||||
Cash from operating activities | (6,178) | (4,704) | |||
CAPEX | (871) | (1,941) | |||
Cash from investing activities | (1,490) | (1,941) | |||
Cash from financing activities | 6,425 | 1,244 | |||
FCF | (4,262) | (5,336) | |||
| Balance | |||||
Cash | 3,069 | 4,351 | |||
Long term investments | |||||
Excess cash | 3,044 | 4,338 | |||
Stockholders' equity | (1,886) | 5,726 | |||
Invested Capital | 11,923 | 6,364 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 12,319 | 12,317 | |||
Price | 6.80 -4.23% | 7.10 15.45% | |||
Market cap | 83,771 -4.21% | 87,454 15.45% | |||
EV | 92,049 | 87,068 | |||
EBITDA | (4,053) | (4,367) | |||
EV/EBITDA | |||||
Interest | 302 | 89 | |||
Interest/NOPBT | |||||